Illumina Board of Directors

Steve MacMillan joined Hologic in December 2013 as President and CEO, and has led a dramatic turnaround at the Company. He was elected Chairman of the Board of Directors in June 2015. From 2005 to 2012, Mr. MacMillan served as President and Chief Executive Officer of Stryker, where he had been President since 2003. During his tenure at Stryker, revenues tripled from $2.8 billion to $8.3 billion.

Prior to 2003, he was a senior executive with Pharmacia, where he oversaw five global businesses with revenues exceeding $2 billion, and he spent 11 years with Johnson & Johnson both in the US and Europe, including as President of the J&J-Merck joint venture.

He began his career with Procter & Gamble following a BA degree in Economics from Davidson College and has previously served on the Boards of Directors of Alere, Boston Scientific and Texas Instruments.

Jacob Thaysen, PhD is Chief Executive Officer of Illumina. Prior to joining the company in 2023, Thaysen served as president of the Life Sciences and Applied Markets Group and Diagnostic and Genomics Group at Agilent; corporate vice president of R&D at Dako; and management consultant at Copenhagen Consultancy Company (now Bain & Co).

Early in his career, he was founder and chief technology officer of Cantion, a research and defense application development company based in Denmark. Thaysen is Chairman of the ALDA Board (Analytical, Life Science and Diagnostic Association) and is a San Diego Chapter member of the American Cancer Society’s CEOs Against Cancer.

Thaysen holds an MSc and PhD in physics from the Technical University of Denmark.

Dr. Arnold has been a director since 2016. She is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology, where she has been on the faculty since 1986. Dr. Arnold received the Nobel Prize in Chemistry (2018) for pioneering directed enzyme evolution; she has used those methods to create enzymes for alternative energy, chemicals, and medicine. She co-chairs the President’s Council of Advisors on Science and Technology. She received the Charles Stark Draper Prize of the US National Academy of Engineering in 2011, the US National Medal of Technology and Innovation from President Obama in 2013, and the Millennium Technology Prize in 2016. She has been elected to all three US National Academies of Science, Medicine, and Engineering, and was appointed by Pope Francis to the Pontifical Academy of Sciences in 2019. Dr. Arnold is a co-inventor on 62 issued US patents.

Dr. Arnold currently serves as a director of Alphabet Inc. and the following privately held companies: of Provivi, an agriculture and pest management company, Aralez Bio, a bioenginieering company, Resilience, a biopharmaceutical manufacturing company, Generate Biomedicines, a drug generation company, and Altos Labs, a biotechnology company. Dr. Arnold received her B.S. in Mechanical and Aerospace Engineering from Princeton University and her Ph.D. in Chemical Engineering from the University of California, Berkeley. She chairs the Advisory Panel of the David and Lucile Packard Foundation Fellowships in Science and Engineering and is the Vice Chair of the Board of Trustees of the Gordon Research Conferences.

Ms. Dorsa has been a director since January 2017. Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a NYSE-listed diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. From February 2008 to April 2009, she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a NYSE-listed pharmaceutical company. From November 2007 to January 2008, Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a Nasdaq-listed life sciences company. From February 2007 to November 2007, she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a NYSE-listed telecommunications company. From 1987 to January 2007, Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing, and Executive Director of U.S. Pricing and Strategic Planning.

Ms. Dorsa also serves as the Chair of the Board of Directors of Biogen Inc. and on the Board of Duke Energy. She previously served on the Board of Intellia Therapeutics, Inc. From 2016 to 2021, she also served on the Board of Trustees of the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund, investment funds within the Goldman Sachs fund complex.

Ms. Dorsa received her M.B.A. from Columbia University and a B.A. from Colgate University.

Dr. Epstein has been a director since November 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. From 2010 to 2012, Dr. Epstein was Chief R&D Officer and President of Medco-UBC, a 2,400 person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes, and comparative effectiveness research on behalf of the biopharmaceutical, medical device, and diagnostics industries. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the boards of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves on the Board of Directors of Fate Therapeutics, Inc. and as Chairperson of the Board of Veracyte, Inc. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association).

Dr. Epstein received his M.D. and B.S. in biomedical science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland.

Dr. Gottlieb has been a director since February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. His work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a Special Partner at the venture capital firm New Enterprise Associates and a Resident Fellow at the American Enterprise Institute for Public Policy Research, and he serves as a director of Pfizer, Aetion, Tempus Labs, National Resilience and the Mount Sinai Medical System. Dr. Gottlieb held several roles in the public and private sectors prior to serving as FDA Commissioner, including serving as a venture partner at New Enterprise Associates from 2007 to 2017. Dr. Gottlieb was previously the FDA's Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as a senior advisor to the FDA Commissioner from 2003 to 2004. He was also a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services in 2004. Dr. Gottlieb has advised the states of Massachusetts, Maryland, and Montana on the Covid response as a member of state advisory boards. He is a contributor to CNBC and CBS Face the Nation.

Dr. Gottlieb received a B.A. in economics from Wesleyan University and his M.D. from the Icahn School of Medicine at Mount Sinai.

Gary S. Guthart, Ph.D. has been director since December 2017. Dr. Guthart is currently President and Chief Executive Officer of Intuitive Surgical, a global leader in the field of robotic-assisted minimally invasive surgery. He joined Intuitive Surgical in April 1996 and has served as the Chief Executive Officer since January 2010. In July 2007, he was promoted to President, having assumed the role of Chief Operating Officer in February 2006. Prior to joining Intuitive Surgical, Dr. Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Dr. Guthart served as a member of the Board of Directors of Affymetrix, Inc. from May 2009 until its acquisition by Thermo Fisher Scientific Inc. in March 2016.

Dr. Guthart received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.

Anna Richo retired from Cargill, Inc., where she was the General Counsel, Chief Compliance Officer and Corporate Secretary.  In addition to her global responsibilities for law and compliance, she oversaw Global Government Relations, Global Security and Shareholder Relations, and was a member of Cargill's Executive Team.  With a law career spanning more than 35 years, Anna wore multiple hats and has extensive experience in compliance and business ethics, intellectual property and corporate litigation.

Before joining Cargill, Anna was executive vice president and general counsel at UCB, a biopharmaceutical company based in Belgium, where she resided for many years.  She also served as senior vice president and chief compliance officer at Amgen, a global biotechnology firm, and as chief litigation counsel, associate general counsel and vice president of law at Baxter Healthcare.  Her broad international experience extends throughout Europe, Latin America and Asia and has served to strengthen her commitment to championing diversity, equity and inclusion in the workplace.

A native New Yorker, Anna holds a Bachelor of Science degree in industrial and labor relations from Cornell University and a Juris Doctor degree from the College of Law at DePaul University.  Anna is a member of the Board of Directors of Exelon Corporation (NASDAQ: EXC), the nation’s largest energy delivery company, a member of the Board of Directors of Illumina, Inc. (NASDAQ: ILMN), a global human genomics DNA sequencing company, a member of the Board of Trustees of DePaul University, and is a member of Children’s Minnesota Governance Board.  Anna formerly served on the Board of Directors of Adamas Pharmaceuticals, a publicly traded neurology company, from 2020-2021, subsequently acquired by Supernus Pharmaceuticals, and on the Board of Directors of Cytyc Corporation, a publicly traded medical diagnostics company, from 1998-2003, subsequently acquired by Hologic Inc. Additionally, Anna served on the Board of Directors for the California Manufacturers & Technology Association, a statewide nonprofit association, from 2000-2003, where she was Vice-Chairman of the Board.

Mr. Schiller has been a director since July 2016. Mr. Schiller is currently an Apple Fellow at Apple Inc. He rejoined Apple Inc. in April 1997 and began serving as Senior Vice President, Worldwide Marketing in February 2002 as a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing, and App Store programs. He has helped Apple create and market some of the best-selling products in the world including the Mac, iPod, iTunes, iPhone, the App Store, Apple TV, and the Apple Watch. Prior to rejoining Apple, Mr. Schiller was Vice President of Product Marketing at Macromedia, Inc. from 1995 to 1997 and Director of Product Marketing at FirePower Systems, Inc. from 1993 to 1995. Prior to that, Mr. Schiller spent six years at Apple in various marketing positions.

Mr. Schiller received a B.S. in biology from Boston College.

Sue Siegel has been a director since February 2019. She has driven game-changing ideas and powered companies that advance industries and improve lives for more than three decades. With vast experience across industries, she is on the forefront of the Fourth Industrial Revolution and is helping companies identify and seize transformative digital opportunities.

Most recently, as GE's Chief Innovation Officer and CEO of GE Ventures & Licensing, Sue oversaw investments in startups, created and scaled new companies, and commercialized GE's intellectual property. She also led strategy planning and oversaw the global marketing function.

Before joining GE, Sue was a Silicon Valley-based healthcare and life sciences VC, leading investments in precision medicine, digital health, and life science tools. Prior to becoming a venture capitalist, Sue led Affymetrix as President and board member, where she led the company's transformation from a pre-revenue startup to a global, multi-billion-dollar market cap genomics leader. Sue also held executive leadership roles at Amersham, DuPont, and Bio-Rad after transitioning to a corporate career from early academic work in molecular biology and biochemistry.

Sue also serves on the boards of Align Technologies (ALGN), Nevro (NVRO), the Kaiser Family Foundation, and is the Chair of MIT's The Engine. Additionally, she serves on the advisory boards for Mass General Brigham's Innovation Growth Board, University of California Innovation Council, RAND Health Care and the U.K. National Health Services Digital Academy. She co-chairs Stanford Medicine Board of Fellows.

Sue was a founding representative board member of NIH's National Center for Advancing Translational Sciences and served on President Obama's Precision Medicine Initiative Working Group.

A leader in technology and business, Sue has been recognized in Fortune's "34 Leaders Who Are Changing Health Care", as one of "The 100 Most Influential Women in Silicon Valley" by Silicon Valley Business Journal and as one of the “Women Continuing to Change the World” by McKinsey & Company. She is an Aspen Institute Henry Crown Fellow and is a featured "Multiplier" in the bestselling book: "Multipliers: How the Best Leaders Make Everyone Smarter."

Ms. Siegel holds a B.S. in Biology from the University of Puerto Rico and a M.S. in Biochemistry and Molecular Biology from Boston University School of Medicine.

Scott Ullem was appointed as a director in 2023. Mr. Ullem is the Chief Financial Officer of Edwards Lifesciences (EW), a global leader in patient-focused innovations for structural heart disease and critical care monitoring. He joined Edwards in 2014 and has responsibility for global finance, information technology, risk management, indirect sourcing and investor relations.

Prior to joining Edwards, Mr. Ullem was Chief Financial Officer of Bemis Company (BMS), a materials science company engaged in design and manufacturing of flexible packaging and pressure sensitive materials.

Previously, Scott was an investment banker at Goldman Sachs in New York and Chicago and later at Bank of America. Mr. Ullem worked with public and private companies in multiple industries on mergers and acquisitions as well as debt and equity financing.

Since 2016, Mr. Ullem has served on the board of directors of Berry Global. He also serves on the board of egnite, a digital health technology company headquartered in Aliso Viejo, California. Mr. Ullem is a Henry Crown Fellow at the Aspen Institute and a former adjunct professor of finance at Northwestern University’s Kellogg School of Management. He received his bachelor's degree in political science from DePauw University and his master's degree in business administration from Harvard Business School.